The laboratories of the research groups of the II. Medical Clinic are located in building N27 on the Research Campus.

Site map

all employees Campus Research - II. Medical Clinic

Working groups in Department of Oncology

WG Acute Leukemia Lab

Head: Prof. Dr. Walter Fiedler and PD Dr. rer. nat. Jasmin Wellbrock

Welcome to the Acute Leukemia Lab: our team investigates the pathophysiology of acute myeloid leukemia using innovative translational approaches. Our main research focus concentrates on the interaction network between leukemic and stromal cells within the bone marrow niche. We pursue the goal to identify novel target structures that will help to improve the therapy of leukemia patients in the future. Another focus is the evaluation of novel immunotherapeutic approaches, with a special focus on the TIGIT immune checkpoint axis.

Further information

ENDomics working group (integrated endothelial research)

Head: Dr. med. Jan K. Hennigs and Dr. rer. nat. Jakob Körbelin

The research group uses systems biology, bioinformatics and cell biology approaches to investigate the molecular causes of endothelial dysfunction and their role in the pathogenesis of vascular lung diseases and carcinomas with the aim of developing novel endothelial-based pharmacological and gene therapy approaches.

Further informations

WG Experimental Oncology

Head: Prof. Dr. Gunhild von Amsberg

The Laboratory for Experimental Oncology is investigating novel marine substances from sea cucumbers and sea sponges that are characterized by high efficacy in various tumours. Based on a combination of unique mechanisms of action, these natural substances can be used to overcome resistance to approved standard cancer treatment therapies.

Further informationen

WG Gastrointestinal Oncology and Response Prediction

Head: PD Dr. Andreas Block, MBA

Chemotherapy is inevitably associated with substantial side effects. Considering low response rates particularly in advanced treatment lines, there is a high demand to identify treatment strategies beforehand in order to guide therapy of cancer in the individual patient. With substantial funding by the Seventh Framework Programs of the European Union and the PROFI R&D funding we examine innovative technologies for the prediction of response in the treatment of colorectal cancer in an international consortium.

Further information

WG Clinical and Experimental Hemostaseology

Head: Prof. Dr. Florian Langer

Solid tumors and hematological malignancies increase the risk for both hemorrhagic and thromboembolic complications. Correct diagnosis and optimal management of paraneoplastic clotting abnormalities require a thorough understanding of the underlying pathophysiology. For this reason, our research group focuses on the cellular and molecular mechanisms of systemic coagulation activation in patients with various types of cancer.

Further Information

WG Palliative Care

Head: Prof. Dr. Karin Oechsle

Scientific research in palliative care evaluates symptoms, concerns and needs of patients with incurable progressive diseases and their relatives to improve their treatment, support, and health care options.

Further information

WG Pulmonary Hypertension

Head: Dr. Lars Harbaum

The development and progression of the rare disease pulmonary arterial hypertension is characterized by vasoconstriction, angiogenesis, vascular remodelling and inflammation, which lead to fundamental structural changes in the pulmonary vascular system. The overall aim is to investigate the relationship between pathophysiological mechanisms and the clinical course of the disease and to identify and establish new therapeutic interventions.

Further informations

WG Translationale Onkologie

Head: Prof. Dr. Meike J. Saul

Our research aims to identify novel microRNA functions in cancer and chronic inflammation and to investigate their role in small extracellular vesicle (sEV)-mediated intercellular communication. In addition, we directly translate our scientific findings into clinical applications to improve personalized treatment strategies and develop new RNA therapeutics.

Further information

WG Experimental Cytogenetics

Head: Prof. Dr. Dr. Judith Dierlamm

Non-Hodgkin-Lymphoma are characterised by specific genetic aberrations. We are investigating the genetic changes in non-Hodgkin-Lymphoma using different techniques like the conventional cytogenetic analysis, fluorescence in-situ hybridisation and PCR. Hereby our path is directed from chromosome to gene.

Further Information